glp-1/gip/glucagon receptor agonist Current Insights, Advantages and Challenges of Small Molecule Glucagon-like Peptide 1 Agonists: A Scoping Review Glucagon-like Peptide-1 Receptor (GLP-1R) Signaling:
Description
The short half-life of native GLP- 1-based therapy in the circulation (approximately two minutes after intravenous administration and one to five hours after subcutaneous administration) posed a problem during its early development [9]

Hernndez-Cascales J

New risks include increased aspiration risk during anesthesia due to delayed gastric emptying and challenges with bowel preparation for colonoscopies [50] [51] [52]

Another exciting avenue is the development of small-molecule GLP-1RAs, designed for oral delivery

What is most disturbing is the rise in children under the age of 5 who are now overweight or living with obesity

Figure 1 shows the average likelihood rating for each food system player across participants with and without GLP-1 medication experience
